ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients

被引：0
|
作者：
Saam A. Mojtahed
Nicole R. Boyer
Saieesh A. Rao
Thomas F. Gajewski
Jennifer Tseng
Kiran K. Turaga
机构：
[1] University of Chicago,Pritzker School of Medicine, Division of Biological Sciences
[2] University of Chicago,Center for Health and the Social Sciences
[3] University of Chicago,Department of Pathology, Division of Biological Sciences
[4] University of Chicago,Department of Surgery, Division of Biological Sciences
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 576
相关论文
共 50 条
  • [31] Comparison of Immunotherapy versus Targeted Therapy Effectiveness in BRAF-Mutant Melanoma Patients and Use of cGAS Expression and Aneuploidy as Potential Prognostic Biomarkers
    Garrison, Zachary
    Clister, Terri
    Bleem, Eric
    Berry, Elizabeth G.
    Kulkarni, Rajan P.
    CANCERS, 2024, 16 (05)
  • [32] A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
    Casabianca, Paul
    Massetti, Marc
    Cotte, Francois-Emery
    Moreau, Romain
    Kassahun, Sarah
    Singh, Prianka
    Kim, Inkyu
    Gaudin, Anne-Francoise
    Piessen, Guillaume
    Leleu, Henri
    PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 689 - 699
  • [33] Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors
    Steffen Wahler
    Alfred Müller
    Sabine Fuchs
    Johann-Matthias von der Schulenburg
    Health Economics Review, 12
  • [34] Adjuvant treatment of high-risk melanoma - cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors
    Wahler, Steffen
    Mueller, Alfred
    Fuchs, Sabine
    von der Schulenburg, Johann-Matthias
    HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [35] Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma
    Hillner, BE
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S18 - S21
  • [36] Cost-effectiveness of adjuvant therapy for treatment of stage II colon cancer in patients with diabetes.
    Dinh, T.
    Alperin, P.
    O'Neil, B. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [37] Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
    Haist, Maximilian
    Stege, Henner
    Rogall, Friederike
    Tan, Yuqi
    von Wasielewski, Imke
    Klespe, Kai Christian
    Meier, Friedegund
    Mohr, Peter
    Kaehler, Katharina C.
    Weichenthal, Michael
    Hauschild, Axel
    Schadendorf, Dirk
    Ugurel, Selma
    Lodde, Georg
    Zimmer, Lisa
    Gutzmer, Ralf
    Debus, Dirk
    Schilling, Bastian
    Kreuter, Alexander
    Ulrich, Jens
    Meiss, Frank
    Herbst, Rudolf
    Forschner, Andrea
    Leiter, Ulrike
    Pfoehler, Claudia
    Kaatz, Martin
    Ziller, Fabian
    Hassel, Jessica C.
    Tronnier, Michael
    Sachse, Michael
    Dippel, Edgar
    Terheyden, Patrick
    Berking, Carola
    Heppt, Markus, V
    Kiecker, Felix
    Haferkamp, Sebastian
    Gebhardt, Christoffer
    Simon, Jan Christoph
    Grabbe, Stephan
    Loquai, Carmen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [38] Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
    Chen, Ping
    Yang, Qing
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS AN ADJUVANT TREATMENT FOR ADULTS AND ADOLESCENTS AGED 12 YEARS AND OLDER WITH RESECTED STAGE IIB/ IIC MELANOMA IN FRANCE
    Saiag, P.
    Meyer, N.
    Zhang, S.
    Jiang, R.
    Mamane, C.
    Chaker, O.
    Bensimon, L.
    Babonneau, A.
    Hidra, R.
    Rey, L.
    Leproust, S.
    Rai, A.
    Vohra, D.
    Khatri, G.
    de Pouvourville, G.
    VALUE IN HEALTH, 2023, 26 (12) : S182 - S182
  • [40] Cost-Effectiveness of Adjuvant Therapy for Stage IIIA Melanoma Is Poor Even When Patients Are Risk-Stratified by Gene Expression Profile
    Hu, Yinin
    Briggs, Andrew
    Marchetti, Michael
    Coit, Daniel
    Bartlett, Edmund
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : E53 - E53
12345